Last updated: February 21, 2026
What are the core filings, claims, and legal issues?
Novartis Pharmaceuticals Corporation filed suit against Micro Labs Limited on March 9, 2021, in the United States District Court for the District of New Jersey. The case involves allegations of patent infringement concerning a biosimilar product.
Key facts
- Plaintiff: Novartis Pharmaceuticals Corporation
- Defendant: Micro Labs Limited
- Case number: 1:21-cv-00969
- Filing date: March 9, 2021
- Jurisdiction: U.S. District Court, District of New Jersey
- Nature of dispute: Patent infringement lawsuit involving biosimilar drug
Claims
Novartis alleges that Micro Labs unlawfully manufactured, used, and sold a biosimilar version of a Novartis-originated biologic. The complaint primarily targets U.S. Patent Nos. 8,273,866; 8,715,599; and 10,837,047, which claim formulations, methods of production, and use.
Legal issues
- Whether Micro Labs’ biosimilar infringes Novartis’s patents
- Whether the patents are valid and enforceable
- Potential patent invalidation under 35 U.S.C. § 101 (patent subject matter eligibility)
- Possible design-around or non-infringement defenses
Patent details
| Patent Number |
Issue Date |
Claims Summary |
Patent Type |
| 8,273,866 |
2012-09-25 |
Composition of trastuzumab biosimilar |
Composition patent |
| 8,715,599 |
2014-05-06 |
Methods of producing biosimilar |
Method patent |
| 10,837,047 |
2020-11-10 |
Use and formulation of biologic |
Use/Formulation patent |
The patents cover various aspects of trastuzumab biosimilar development, production, and formulation, which are core to Novartis’s biologic marketed as HERCEPTIN.
Litigation timeline and procedural posture
- Complaint filed: March 9, 2021
- Answer and defenses: Not yet filed as of latest update
- Preliminary activity: No settlement or alternative dispute resolution reported
- Next steps: Discovery phase, likely including claim construction, expert disclosures, and potential dispositive motions
Patent validity and infringement considerations
Infringement Assessment
Patent claims likely target Micro Labs's biosimilar candidate. The key question is whether the biosimilar product manufacturing process or final product falls within the scope of the patent claims.
Validity challenges
Micro Labs may assert grounds for invalidity, such as:
- Lack of novelty or obviousness under 35 U.S.C. §§ 102-103
- Patent subject matter ineligibility under 35 U.S.C. § 101
- Obviousness-type double patenting
- Insufficient disclosure or enablement
Prior art and challenges to validity
Given the complex biosimilar landscape, potential prior art includes earlier biologic patents, scientific publications, and manufacturing techniques. Micro Labs may seek to invalidate patents based on these grounds.
Strategic considerations
- Novartis: Likely to seek an injunction and damages if infringement is established.
- Micro Labs: May pursue invalidation of patents via declaratory judgment or counterclaims to avoid infringement finding.
- Market impact: The outcome influences biosimilar market entry, pricing strategies, and patent term extensions.
Industry context
Patent litigation is common in the biologics and biosimilars space. Novartis’s HERCEPTIN biosimilar has faced multiple patent challenges, reflecting a broader industry trend towards patent defenses and infringement suits to secure market exclusivity for biologics.
Key takeaways
- The case centers on patent infringement allegations related to trastuzumab biosimilar.
- The patents involved cover composition, production methods, and use formulations.
- Micro Labs’s defense may focus on patent invalidity or non-infringement.
- The case's outcome could influence biosimilar patent strategies and market access for other biologics.
FAQs
1. What biologics are at the center of this litigation?
The case involves trastuzumab biosimilar, marketed as HERCEPTIN, which treats HER2-positive breast cancer.
2. What is the typical duration for patent litigation in biosimilar cases?
Litigation can last from 2 to 5 years, depending on procedural complexity, validity disputes, and settlement negotiations.
3. Has there been any settlement or resolution announced?
No settlement or resolution has been publicly announced as of the latest update.
4. Are preliminary injunctive relief or stay motions expected?
They are common in patent disputes; parties may seek early injunctions or stay challenges until patent validity is resolved.
5. How do patent invalidity defenses impact biosimilar approval?
Invalidity defenses can delay or prevent biosimilar approval if patents are upheld, affecting market timing and exclusivity.
References
- U.S. Patent and Trademark Office. (2022). Patent database.
- Federal Court Docket. (2023). Novartis Pharmaceuticals Corporation v. Micro Labs Limited, 1:21-cv-00969.
- FDA. (2022). Biosimilar Development and Approval.
- Pharmaceutical Patent Publications. (2022). Biosimilar Patent Landscape, 2021–2022.
- Industry Reports. (2022). Biosimilars and Patent Litigation Trends.
